Recent Developments in Biotech

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across molecular diagnostics. Topics embrace innovative molecular diagnostics platforms for cancer management and novel CAR-T cell platforms for the management of infectious diseases, as well as, recent registration for IPO (Initial Public Offering) and clinical trials. The corresponding clinical trials scenario is also depicted.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of

Table of Contents

Recent Developments in BiotechRecent Advances in BiotechInnovative Molecular Diagnostic Platform for Cancer ManagementARMO BioSciences Files Registration for Initial Public OfferingMenlo Therapeutics Inc., Files for IPONovel CAR-T Cell Platform for the Management of HIV InfectionClinical Trial Analysis and Industry InteractionsSummary of Clinical Studies of ARMO BioSciencesSummary of Clinical Studies of ARMO BioSciences (continued)Key Contacts




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.